Edwards Lifesciences (NYSE:EW – Free Report) had its price objective decreased by Citigroup from $83.00 to $77.00 in a research note issued to investors on Tuesday, Benzinga reports. Citigroup currently has a buy rating on the medical research company’s stock. A number of other equities research analysts have also recently weighed in on EW. Piper […]

Lamb Weston (NYSE:LW – Get Free Report) had its price target lifted by stock analysts at Citigroup from $75.00 to $76.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the specialty retailer’s stock. Citigroup’s target price would suggest a potential upside of […]

Citigroup upgraded shares of Shell (NYSE:SHEL – Free Report) to a hold rating in a report issued on Wednesday morning, Zacks.com reports. SHEL has been the topic of a number of other reports. Berenberg Bank upgraded shares of Shell to a strong-buy rating in a report on Monday, August 5th. Royal Bank of Canada upgraded […]

EQT (NYSE:EQT – Get Free Report) was upgraded by research analysts at Citigroup from a “neutral” rating to a “buy” rating in a report released on Thursday, Marketbeat.com reports. The brokerage presently has a $44.00 price target on the oil and gas producer’s stock, up from their previous price target of $37.00. Citigroup’s price target […]

Citigroup upgraded shares of Equinor ASA (NYSE:EQNR – Free Report) to a strong sell rating in a research report released on Wednesday morning, Zacks.com reports. Other research analysts have also issued reports about the stock. Morgan Stanley lowered shares of Equinor ASA from an equal weight rating to an underweight rating and cut their target […]

Citigroup (NYSE:C – Free Report) had its price objective lifted by Oppenheimer from $87.00 to $92.00 in a report published on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Other equities analysts have also issued reports about the company. The Goldman Sachs Group reduced their price target on Citigroup from […]

Integra LifeSciences (NASDAQ:IART – Free Report) had its price objective decreased by Citigroup from $20.00 to $16.00 in a research note released on Tuesday morning, Benzinga reports. Citigroup currently has a sell rating on the life sciences company’s stock. IART has been the topic of a number of other reports. Morgan Stanley increased their price […]

Citigroup upgraded shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a neutral rating to a buy rating in a report published on Tuesday morning, MarketBeat reports. The firm currently has $400.00 price objective on the medical research company’s stock, up from their previous price objective of $350.00. BIO has been the topic of several […]